Dr. Staci M. Kallish, DO

Dr. Kallish practices at Perelman Center For Advanced Medicine in Philadelphia, Pennsylvania.

Dr. Kallish's NPI, 1811152796, was assigned on July 21, 2008. Dr. Kallish graduated from Rowan University School of Osteopathic Medicine in 2005. Dr. Kallish holds Pennsylvania license OS014273.

Dr. Kallish's primary practice is Perelman Center for Advanced Medicine, at 3400 Civic Center Blvd Fl 2 Fl 2, Philadelphia, PA 19104. The practice phone is (215) 615-4949.

Dr. Kallish's primary practice is Perelman Center For Advanced Medicine in Philadelphia, Pennsylvania. Dr. Kallish is also affiliated with Hospital of the University of Pennsylvania. The medical group on file is Penn Medicine Lancaster General Health.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Kallish practices, 2 sites in all. Vendor and product names are available with a free account.

Clinical genetics (m.d.) is Dr. Kallish's primary specialty in the NPI Registry, under taxonomy code 207SG0201X. Dr. Kallish is board certified in clinical biochemical genetics by the American Board of Medical Genetics and Genomics. Dr. Kallish is licensed in Pennsylvania.

Dmand AI lists intellectual and developmental disabilities among the conditions Dr. Kallish treats.

CMS data shows 78 Medicare services from Dr. Kallish across 3 procedure codes in 2024, for 52 Medicare patients. Medicare paid $7,387 for them. Every service was in a facility, such as a hospital, rather than an office.

CMS counts 52 Medicare patients who saw Dr. Kallish in 2024. The largest group is 65 to 74, with 29 patients. 67% of them have high cholesterol, and 52% have high blood pressure. 23% are also on Medicaid. Their average risk score is 1.89, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Kallish's median patient age at 38, with 64% women.

In 2024, Dr. Kallish wrote 111 Medicare Part D claims for 13 patients. 16% of them were for generic drugs. CMS names the drug for 92 of them, across 5 drugs with 11 or more claims each, at $2,575,052 in total drug cost. In 2023, CMS named 62 claims across 4 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 85 out of 100 for Dr. Kallish for performance year 2024, reported as part of a group. Dr. Kallish accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Kallish as offering telehealth.

Dmand AI links 21 papers to Dr. Kallish, published from 2011 to 2025. 2012 was the busiest year, with 3. The most frequent topics are Phenotype, Abnormalities, Multiple and DiGeorge Syndrome. Dr. Kallish has published most often in Am J Med Genet A. Dr. Kallish's most frequent co-authors are Elaine H. Zackai, MD, Theodore George Drivas, MD, PhD and Mona Al Mukaddam, MD.

CMS Open Payments shows 155 general payments to Dr. Kallish from 7 drug and device companies from 2016 to 2025. Consulting fees make up the largest share, 74% of the total. Amicus Therapeutics, Inc. paid the most, $118,050.

Dr. Kallish graduated from Rowan University School of Osteopathic Medicine in 2005. Dr. Kallish is a member of AOA.

Dr. Kallish is in network with 22 carriers, including Aetna, Elevance and United Healthcare. PPO plans come from the most carriers, 12. Check the plan with the practice before a visit.